Partnership Could be a Model for Orphan Disease “Adoption”

Rare and orphan disease treatments could be fostered by a newly formed collaboration between Fidelity Biosciences, a subsidiary of Fidelity Investments, and Regenx Biosciences. Together, the companies have formed Dimension Therapeutics, a gene therapy company focused on “developing novel treatments for rare diseases.” With Series A financing and rights to a portfolio of over 100 patents and patent applications, Dimension Therapeutics will focus on innovations in gene therapy, “a fundamental method of disease intervention, changing a patient’s genetic code to treat genetic disease, and in some cases providing a potential lifelong benefit following a single treatment.” With Dimension Therapeutics focusing on developing treatments for rare and orphan diseases, let’s hope they are thinking about ALS as a potential indication of interest!

Click here to read the full story.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail